- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes), Mild Cognitive Impairment
- Interventions
- Not listed
- Lead sponsor
- Novoic Limited
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Santa Ana, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 34
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Aging, Mental Disorder, Eating, Healthy, Physical Inactivity, Prodromal Symptoms, Sleep, Alzheimer Disease, Dementia, Circadian Rhythm Disorders
- Interventions
- Behavioral Self-Monitoring + Motivational Interviewing
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Alzheimer Disease, Dementia, Alzheimer Type
- Interventions
- E2609, Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 21
- States / cities
- Bellflower, California • Costa Mesa, California • Glendale, California + 18 more
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Aging
- Interventions
- repetitive transcranial magnetic stimulation (rTMS)
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Alzheimer Disease, Dementia, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease
- Interventions
- Financial Incentives, Message
- Behavioral
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 44,844 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Martinez, California
- Conditions
- Alzheimer Disease, Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Memory Loss, Memory Disorders, Memory Impairment
- Interventions
- Biomarker Data Collection
- Other
- Lead sponsor
- GAP Innovations, PBC
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 1,002 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 16
- States / cities
- Aventura, Florida • Coral Gables, Florida • Lady Lake, Florida + 13 more
- Conditions
- Prodromal Alzheimer's Disease, Preclinical Alzheimer's Disease, Healthy Aging, Cognitive Decline
- Interventions
- Active rTMS, Sham rTMS
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 40 Years to 99 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Prodromal Alzheimer's Disease, Mild Cognitive Impairment, Subjective Cognitive Complaints
- Interventions
- Digital Memory Notebook (DMN) Application
- Behavioral
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Alzheimer's Disease
- Interventions
- Crenezumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 806 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 48
- States / cities
- Scottsdale, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 44 more
- Conditions
- Alzheimer Disease
- Interventions
- Gantenerumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 1,053 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 33
- States / cities
- Tucson, Arizona • Irvine, California • Sacramento, California + 29 more
- Conditions
- Alzheimer Disease
- Interventions
- Gantenerumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 975 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Fayetteville, Arkansas + 39 more
- Conditions
- Alzheimer Disease (AD)
- Interventions
- [18F]GTP1, [18F]PI-2620, [18F]MK-6240
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Alzheimer's Disease
- Interventions
- ALZT-OP1a, ALZT-OP1b, Placebo ALZT-OP1a, Placebo ALZT-OP1b
- Drug · Other
- Lead sponsor
- AZTherapies, Inc.
- Industry
- Eligibility
- 55 Years to 79 Years
- Enrollment
- 620 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 69
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 56 more
- Conditions
- Alzheimer Disease, Alzheimer's Disease (Incl Subtypes), Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Mild Cognitive Impairment, Normal Cognition
- Interventions
- Not listed
- Lead sponsor
- Novoic Limited
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Santa Ana, California
- Conditions
- Alzheimer's Disease
- Interventions
- Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb), Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 32
- States / cities
- Tucson, Arizona • Laguna Hills, California • Lomita, California + 28 more
- Conditions
- Alzheimer Disease
- Interventions
- Gantenerumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 7
- States / cities
- Atlantis, Florida • Maitland, Florida • Ocala, Florida + 4 more
- Conditions
- Alzheimer's Disease
- Interventions
- Gantenerumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 799 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • La Jolla, California • New Haven, Connecticut + 21 more
- Conditions
- Alzheimer's Disease
- Interventions
- [18F]GTP1
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 16
- States / cities
- New Haven, Connecticut • Stamford, Connecticut • Fort Myers, Florida + 13 more
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease
- Interventions
- Senicapoc, Placebo Tablet
- Drug · Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 2
- States / cities
- Sacramento, California • Walnut Creek, California
- Conditions
- Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease, Alzheimer's Disease
- Interventions
- Placebo (Study Part 1a), ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a, ACI-24.060 at Dose C in Study Part 1a, ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b, Placebo (Study Part 2), ACI-24.060 at Dose A in Study Part 2, ACI-24.060 at Dose B in Study Part 2, ACI-24.060 at Dose C in Study Part 2, Placebo (Study Part 1b), ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b
- Biological
- Lead sponsor
- AC Immune SA
- Industry
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Lady Lake, Florida • Orlando, Florida + 9 more
- Conditions
- Alzheimer's Disease
- Interventions
- Avagacestat, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 45 Years to 90 Years
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 39 more
- Conditions
- Early Alzheimer's Disease
- Interventions
- Lecanemab IV, Placebo, Lecanemab SC
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 1,906 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 112
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 84 more
- Conditions
- Alzheimer's Disease
- Interventions
- Crenezumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 813 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 66
- States / cities
- Phoenix, Arizona • Encino, California • Long Beach, California + 56 more
- Conditions
- Alzheimer's Disease
- Interventions
- Elenbecestat, Placebo
- Drug
- Lead sponsor
- Eisai Co., Ltd.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 2,212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 88
- States / cities
- Chandler, Arizona • Colton, California • Costa Mesa, California + 68 more